Plain-English translation of NCT06655896 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is comparing two treatments for severe diffuse cutaneous systemic sclerosis (a serious condition where skin hardens and internal organs can be affected). One group will receive , a new type of treatment that uses your own immune cells, while another group receives , a medication already used for this disease. The study will track how well each treatment works and how safe it is over five years.
Systemic sclerosis can be life-threatening and many patients don't respond well enough to current treatments. This trial is testing whether this new cell-based treatment might help people whose disease has not been controlled by standard options.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either the new cell therapy or the standard medication. If you receive the new treatment, your own immune cells will be collected, modified in a laboratory, and then returned to your body. You'll have regular check-in visits over five years to monitor how well the treatment is working, check for side effects, and complete various tests. After the main study ends, you'll continue in a long-term follow-up program to track your health over time.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States